

110



ΕΛ.Ε.ΨΥ.
ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ ΚΛΙΝΙΚΗΣ
ΨΥΧΟΦΑΡΜΑΚΟΛΟΓΙΑΣ

ΠΑΝΕΛΛΗΝΙΟ
ΣΥΝΕΔΡΙΟ ΚΛΙΝΙΚΗΣ
ΨΥΧΟΦΑΡΜΑΚΟΛΟΓΙΑΣ

20-22 ΑΠΡΙΛΙΟΥ 2023
Hotel DU LAC - ΙΩΑΝΝΙΝΑ



ΜΕ ΔΙΕΘΝΗ ΣΥΜΜΕΤΟΧΗ



John H. Krystal, M.D.

Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience, and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale School of Medicine, and the Yale Psychiatry Residency Training Program. He

has published extensively on the neurobiology and treatment of schizophrenia, alcoholism, PTSD, and depression. Notably, his laboratory discovered the rapid antidepressant effects of ketamine in humans. He directs/co-directs the Yale Center for Clinical Investigation (CTSA), NIAAA Center for the Translational Neuroscience of Alcoholism, and Clinical Neuroscience Division of the National Center for PTSD (VA). Dr. Krystal is a member of the U.S. National Academy of Medicine; co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; Fellow of the American Association for the Advancement of Science (AAAS); and editor of *Biological Psychiatry* (IF=12.8). He chaired the NIMH Board of Scientific Counselors and has served as a member of the NIMH National Mental Health Advisory Council and the NIAAA National Alcohol Advisory Council. He is past president of the American College of Neuropsychopharmacology (ACNP) and the International College of Neuropsychopharmacology (CINP). He is a co-founder and Chief Scientific Advisor for Freedom Biosciences and he serves in other industry advisory capacities.